PRCT Stock Forecast & Price Target

PROCEPT BioRobotics Corp is poised for significant growth, as it anticipates a more than 50% year-over-year increase in procedure volumes in the second half of 2026, driven by effective commercial initiatives. The company demonstrated strong operational performance in Q3 2025, reporting sales of $83.3 million, representing a 43% increase year-over-year, which surpassed both target and consensus estimates. Additionally, robust domestic and international capital system placements, which outperformed previous guidance, indicate a positive trajectory for sustainable double-digit growth fueled by increased BPH surgery center utilization.

PROCEPT BioRobotics Corp has experienced a disappointing financial performance, with fourth-quarter revenue reported at 19% below consensus expectations, prompting a downward revision of FY26 sales guidance to a range of $390-410 million, which is also 5% below market consensus of $422 million. The company's sales in the U.S. are projected to be particularly weak, estimated at $340-359 million, reflecting a 7% shortfall compared to consensus estimates of $374 million. Additionally, the reduction in sales of handpieces, attributed to the end of bulk purchase discounts and inventory destocking, has further contributed to the company’s negative outlook, highlighting pressures that hospitals face post-COVID and amid ongoing macroeconomic challenges.